Candriam SCA’s MoonLake Immunotherapeutics MLTX Stock Holding History

Candriam SCA’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15M	Sell	769,766 -48,360	-6%	-$877K	0.07%	237
2026 Q1	$15.2M	Buy	818,126 +683,797	+509%	+$11.3M	0.08%	226
2025 Q4	$1.77M	Buy	134,329 +687	+0.5%	+$8.11K	0.01%	518
2025 Q3	$958K	Sell	133,642 -11,188	-8%	-$583K	0.01%	583
2025 Q2	$6.84M	Sell	144,830 -29,690	-17%	-$1.21M	0.04%	306
2025 Q1	$6.82M	Sell	174,520 -52,956	-23%	-$2.28M	0.04%	280
2024 Q4	$12.3M	Sell	227,476 -11,524	-5%	-$588K	0.07%	234
2024 Q3	$12M	Hold	239,000	–	–	0.07%	246
2024 Q2	$10.5M	Hold	239,000	–	–	0.06%	250
2024 Q1	$12M	Buy	239,000 +54,000	+29%	+$2.93M	0.08%	236
2023 Q4	$11.2M	Buy	+185,000	New	+$9.53M	0.08%	236

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Candriam SCA's MLTX Position: Q2 2026 in Review

Candriam SCA reduced its MoonLake Immunotherapeutics (MLTX) stake by 5.9% in Q2 2026, selling an estimated $877K and leaving 769,766 shares worth $15M. The position accounts for 0.07% of the portfolio, ranked #237.

Candriam SCA first reported a position in MLTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $15.2M in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Candriam SCA held 769,766 shares of MoonLake Immunotherapeutics worth $15M as of Q2 2026.
Candriam SCA sold 48,360 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $877K.
MoonLake Immunotherapeutics made up 0.07% of Candriam SCA's portfolio in Q2 2026, its #237 holding.
Candriam SCA first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 11 quarters since.
Candriam SCA's MoonLake Immunotherapeutics position peaked at $15.2M in Q1 2026.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.